Management ChangeApr 22, 2026, 08:02 AM
PMV Pharma Appoints Laurie Stelzer as Board Chair
AI Summary
PMV Pharmaceuticals announced Laurie Stelzer will become the new Chair of its Board of Directors, effective June 4, 2026, succeeding Rich Heyman, Ph.D. Ms. Stelzer brings over 25 years of senior finance and business development experience in the biopharmaceutical industry. This leadership transition occurs as the company progresses with its PYNNACLE clinical trial and anticipates submitting a New Drug Application for rezatapopt in platinum-resistant/refractory ovarian cancer in Q1 2027.
Key Highlights
- Laurie Stelzer appointed Board Chair, effective June 4, 2026.
- Rich Heyman's term as Chair and Board member expires June 4, 2026.
- Ms. Stelzer brings over 25 years of biopharma finance and leadership experience.
- Company anticipates NDA submission for rezatapopt in Q1 2027.